DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hfq5pn/ym_biosciencess) has announced the addition of the YM Biosciences's JAK-2 Inhibitor for Myelofibrosis - Could this be the best in class? report to their offering.
Several companies are developing JAK2 inhibitors for the treatment of myelofibrosis (MF) and other myeloproliferative disorders. Incyte's and Novartis's ruxolitinib is the compound furthest along in development, having completed two positive phase III trials. It could be on the market by year-end.
Last December, YM Biosciences reported intriguing early data for CYT387, suggesting an unprecedented positive effect on anemia. If confirmed, this effect could represent an important marketing advantage given that anemia is strongly predictive of survival in MF. However, investors have questioned whether this effect is real. In this report, we dissect CYT387's anemia effect, highlighting what is problematic but also what is solid information. In addition, we review the JAK2 inhibitor landscape, the unmet need beyond ruxolitinib, the differentiating characteristics among the compounds and the issues that could drive market success in this competitive field.
Key Topics Covered:
MYELOFIBROSIS - A MYELOPROLIFERATIVE DISORDER
1. Primary Myelofibrosis
2. Secondary myelofibrosis
- Polycythemia vera
- Essential thrombocythemia
4. The Role Of Jak2
1. Preclinical studies
2. Phase I/II
- Favorable Anemia Response
1. The unmet medical need in myelofibrosis is great
2. JAK2 as a target for treatment of myeloproliferative disorders
3. How to measure clinical benefit in myelofibrosis
4. What JAK2 inhibitors can and cannot do in myelofibrosis
5. Incyte's ruxolitinib will be first to market and the standard to beat
6. What are Incyte's drug's limitations? What is the remaining unmet need?
7. Improvement in anemia could represent a key marketing advantage
8. CYT387 investigators reported a positive effect on anemia - Is it real?
9. CYT387 trial definitions relative to IWG criteria
10. Anemia response driven by transfusion dependent patients
11. The IWG transfusion status criteria are in flux
12. Revisions to transfusion definitions are underway - the Gale criteria
13. Lessons from Revlimid's approval in myelodysplastic syndrome
14. What does all this mean for CYT378 and the anemia response?
15. Other caveats regarding CYT378: spleen and symptom assessment
16. Safety profile - some signals to watch out
17. Racing against time to initiate phase III
1. Other Jak2 Inhibitors In Development
- Incyte's and Novartis' ruxolitinib (INCB018424)
- S*Bio's SB1518
- Sanofi's TG101348
2. Other drugs in development for MF
THE MARKET OPPORTUNITY
For more information visit http://www.researchandmarkets.com/research/hfq5pn/ym_biosciencess